retatrutide phase 2 results obesity nejm 2023 VisualAbstract: reduces body weight by 17.5% in patients with Retatrutide Phase 3: TRIUMPH Program

Contribution of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1C) // Diabetes Care

Two studies looked at the vision outcomes for people with Type 2 diabetes who take Mounjaro and other GLP-1 medications over a two-year period

View Product The Clinical Trial Numbers by Gender The Phase 2 trial (TRIUMPHANT-2) enrolled 338 participants across multiple dosing groups, with the 12mg cohort providing the most telling data on gender-based outcomes

Order issues resolution: Shipping problems, quality concerns, or incorrect orders require resolution processes

doi: 10.1016/j.semcdb.2018.04.016 20 WittMReutterK

Many individuals with these conditions have used GLP-1 agonists successfully